ArticleScientific reports2023
The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Effects of empagliflozin on uric acid levels during acute heart failure recompensation: A sub-analysis of the EMPAG-HF trial (Effects of Empagliflozin on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure).European journal of heart failure · 2025Trial
- Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.Diabetes, obesity & metabolism · 2025 · on this mapTrial
- Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Gout Risk: A Population-Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation.Diabetes, obesity & metabolism · 2026Article
- Effect of sodium-glucose cotransporter-2 inhibitors on uric acid in patients with heart failure and preserved ejection fraction: a retrospective analysis in real word.BMC cardiovascular disorders · 2026Article
- Exploration and clinical analysis of the correlation between the triglyceride-glucose index and hyperuricemia in patients with type 2 diabetes: a real-world, retrospective, cross-sectional study with subsequent cohort analysis.BMC endocrine disorders · 2026Article
- Relationship between changes in uric acid levels and renal function during 12 months of treatment with luseogliflozin.Diabetology international · 2026Article
- Efficacy of dapagliflozin on uric acid in patients with moderate-to-severe chronic kidney disease.Clinical and experimental nephrology · 2026Article
- Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors for Uricosuria.Electrolyte & blood pressure : E & BP · 2025Review
- Research progress on the effects of sodium-glucose linked transporter 2 inhibitors on multiple metabolic disorders in metabolic syndrome.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
- SGLT2 Inhibitors and Uric Acid Homeostasis.Gout, urate, and crystal deposition disease · 2024Article
- Fractional Excretion of Urate is Positively Associated with Type 2 Diabetes in HUA Patients: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exhibit renoprotective effect in patients with chronic kidney disease (CKD) and reduce serum uric acid (UA) in patients with diabetes mellitus. However, it is not clarified whether SGLT2i reduce serum UA levels in patients with advanced CKD. This study aimed to investigate the impact of SGLT2i on change in serum UA levels in patients with advanced CKD. Data of 121 Japanese patients with CKD who were newly administered 10 mg dapagliflozin in our department between August 2021 and August 2022 were analyzed. Changes in UA and fractional excretion of UA (FEUA) were analyzed using multiple regression analysis. Of 75 patients, 21 (28.0%) patients, 24 (32.0%) patients, 29 (38.7%) patients, and 1 (1.3%) patient were categorized as having CKD stage 3a, 3b, 4, and 5, respectively. The median age was 67 years, and 72.0% were male. 23 (30.7%) of patients had diabetes mellitus. The median estimated glomerular filtration rate, serum UA, and FEUA were 35.7 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.